ATE457988T1 - A2a-adenosin-rezeptor-antagonisten - Google Patents
A2a-adenosin-rezeptor-antagonistenInfo
- Publication number
- ATE457988T1 ATE457988T1 AT07796492T AT07796492T ATE457988T1 AT E457988 T1 ATE457988 T1 AT E457988T1 AT 07796492 T AT07796492 T AT 07796492T AT 07796492 T AT07796492 T AT 07796492T AT E457988 T1 ATE457988 T1 AT E457988T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- adenosine receptor
- alkyl
- compounds
- cns diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81651606P | 2006-06-26 | 2006-06-26 | |
PCT/US2007/014886 WO2008002596A2 (en) | 2006-06-26 | 2007-06-25 | Adenosine a2a receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE457988T1 true ATE457988T1 (de) | 2010-03-15 |
Family
ID=38846284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07796492T ATE457988T1 (de) | 2006-06-26 | 2007-06-25 | A2a-adenosin-rezeptor-antagonisten |
Country Status (10)
Country | Link |
---|---|
US (1) | US7713985B2 (ja) |
EP (1) | EP2038285B1 (ja) |
JP (1) | JP2010509189A (ja) |
CN (1) | CN101506215A (ja) |
AT (1) | ATE457988T1 (ja) |
CA (1) | CA2655987A1 (ja) |
DE (1) | DE602007004851D1 (ja) |
ES (1) | ES2339502T3 (ja) |
MX (1) | MX2009000104A (ja) |
WO (1) | WO2008002596A2 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009222047A1 (en) * | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists |
WO2009136578A1 (ja) * | 2008-05-09 | 2009-11-12 | パイオニア株式会社 | 空間映像表示装置 |
AU2010222289B2 (en) | 2009-03-13 | 2013-07-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
TWI548411B (zh) | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
EP2509983B1 (en) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
CN103261202B (zh) * | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
JP6042968B2 (ja) * | 2012-04-20 | 2016-12-14 | ユセベ ファルマ ソシエテ アノニム | パーキンソン病の処置方法 |
CN102659620A (zh) * | 2012-05-18 | 2012-09-12 | 东南大学 | 2,4-双(三氟甲基)苄肼的合成方法 |
WO2014101113A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
CN105025899B (zh) * | 2012-12-28 | 2017-08-18 | 默沙东公司 | 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物 |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
KR102653800B1 (ko) | 2018-11-30 | 2024-04-01 | 머크 샤프 앤드 돔 엘엘씨 | 아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도 |
WO2021191376A1 (en) | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
WO2021191379A1 (en) | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
WO2021191380A1 (en) | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
CN115867282A (zh) | 2020-03-26 | 2023-03-28 | 赫普泰雅治疗有限公司 | 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955465A (en) * | 1996-03-22 | 1999-09-21 | Neurogen Corporation | 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones |
WO2004058974A1 (en) * | 2002-12-27 | 2004-07-15 | Actar Ab | A method of drug screening to select agonists or antagonists of g protein coupled receptors (gpcr). |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
ATE538123T1 (de) * | 2005-09-19 | 2012-01-15 | Schering Corp | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors |
-
2007
- 2007-06-25 CN CNA2007800313042A patent/CN101506215A/zh active Pending
- 2007-06-25 MX MX2009000104A patent/MX2009000104A/es active IP Right Grant
- 2007-06-25 EP EP07796492A patent/EP2038285B1/en active Active
- 2007-06-25 WO PCT/US2007/014886 patent/WO2008002596A2/en active Application Filing
- 2007-06-25 AT AT07796492T patent/ATE457988T1/de not_active IP Right Cessation
- 2007-06-25 CA CA002655987A patent/CA2655987A1/en not_active Abandoned
- 2007-06-25 JP JP2009518245A patent/JP2010509189A/ja not_active Withdrawn
- 2007-06-25 DE DE602007004851T patent/DE602007004851D1/de active Active
- 2007-06-25 ES ES07796492T patent/ES2339502T3/es active Active
- 2007-06-25 US US11/767,624 patent/US7713985B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2038285A2 (en) | 2009-03-25 |
MX2009000104A (es) | 2009-01-23 |
ES2339502T3 (es) | 2010-05-20 |
US20080255156A1 (en) | 2008-10-16 |
CN101506215A (zh) | 2009-08-12 |
WO2008002596A2 (en) | 2008-01-03 |
CA2655987A1 (en) | 2008-01-03 |
JP2010509189A (ja) | 2010-03-25 |
US7713985B2 (en) | 2010-05-11 |
EP2038285B1 (en) | 2010-02-17 |
DE602007004851D1 (de) | 2010-04-01 |
WO2008002596A3 (en) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
JO2613B1 (ar) | مركبات عضوية | |
PL1891029T3 (pl) | Związki organiczne do leczenia stanów zapalnych lub alergicznych | |
MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
GEP20115174B (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
IL176110A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
MX2007013624A (es) | Inhibidores de proteina cinasa. | |
NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
TW200637863A (en) | Organic compounds | |
TW200630366A (en) | Organic compounds | |
MX2012004848A (es) | Compuestos heterociclicos triciclicos. | |
HK1138262A1 (en) | Novel phosphodiesterase inhibitors | |
MX2010001020A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. | |
MX2010006230A (es) | Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3. | |
TW200639156A (en) | New compounds | |
MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. | |
MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
MX2010002938A (es) | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. | |
TW200745130A (en) | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | |
WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
MX2009011059A (es) | Aminopirimidinas utiles como inhibidores de cinasas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |